Status:
COMPLETED
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Advanced Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE1
Brief Summary
To determine safety and maximum tolerated dose of brivanib alaninate when administered in combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel chemotherapy to subjects wit...
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
- Histologic/cytologic diagnosis of advanced or metastatic solid tumors
- Life expectancy \>= 3 months
- Able to swallow tablets/capsules
Exclusion
- Pregnant or breastfeeding women
- No more than 4 previous chemotherapy regimens in the advanced or metastatic setting (excluding prior adjuvant or hormonal / immuno / biologic antibody therapies
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2015
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT00798252
Start Date
March 1 2009
End Date
May 1 2015
Last Update
July 7 2015
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Usc/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
2
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
3
Wayne State University
Detroit, Michigan, United States, 48201
4
Local Institution
Edmonton, Alberta, Canada, T6G 1Z2